|
注册号: Registration number: |
ChiCTR2600124050 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-06 17:19:19 |
|
注册时间: Date of Registration: |
2026-05-06 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
自助式正念干预对乳腺癌患者死亡焦虑的效果研究及卫生经济学评价 |
|
Public title: |
Effectiveness of Self-Directed Mindfulness-Based Intervention on Death Anxiety in Breast Cancer Patients: A Randomized Controlled Trial and Health Economic Evaluation |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
自助式正念干预对乳腺癌患者死亡焦虑的效果研究及卫生经济学评价 |
|
Scientific title: |
Effectiveness of Self-Directed Mindfulness-Based Intervention on Death Anxiety in Breast Cancer Patients: A Randomized Controlled Trial and Health Economic Evaluation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈付蓉 |
研究负责人: |
陈付蓉 |
|
Applicant: |
Chen Furong |
Study leader: |
Chen Furong |
|
申请注册联系人电话: Applicant telephone: |
+86 135 4824 9849 |
研究负责人电话:
Study leader's |
+86 135 4824 9849 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2013580534@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
2013580534@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市越秀区东风西路195号 |
研究负责人通讯地址: |
广东省广州市越秀区东风西路195号 |
|
Applicant address: |
No. 195 Dongfeng West Road, Yuexiu District, Guangzhou, Guangdong Province, China |
Study leader's address: |
No. 195 Dongfeng West Road, Yuexiu District, Guangzhou, Guangdong Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
广州医科大学 |
||
|
Applicant's institution: |
Guangzhou Medical University |
||
|
研究负责人所在单位: |
广州医科大学 广州医科大学附属肿瘤医院 |
||
|
Affiliation of the Leader: |
Guangzhou Medical University Affiliated Cancer Hospital and Institute of Guangzhou Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY-2026014-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广州医科大学附属肿瘤医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Guangzhou Medical University Cancer Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-06 00:00:00 | ||
|
伦理委员会联系人: |
程甜甜 |
||
|
Contact Name of the ethic committee: |
Cheng Tiantian |
||
|
伦理委员会联系地址: |
广东省广州市越秀区横枝岗路78号 |
||
|
Contact Address of the ethic committee: |
No. 78 Hengzhigang Road, Yuexiu District, Guangzhou City, Guangdong Province, China. |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 6667 3666 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
广州医科大学附属肿瘤医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Cancer Hospital and Institute of Guangzhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市越秀区横枝岗路78号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 78 Hengzhigang Road, Yuexiu District, Guangzhou City, Guangdong Province, China. |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
课题组经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Research Group Funding |
||||||||||||||||||||||
|
研究疾病: |
乳腺癌 |
||||||||||||||||||||||
|
Target disease: |
Breast cancer |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
(1) 明确乳腺癌幸存者死亡焦虑核心节点并分析其影响因素; (2) 构建基于自助式正念干预的乳腺癌幸存者死亡焦虑干预方案; (3) 评价自助式正念干预用于乳腺癌幸存者死亡焦虑干预效果的有效性和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) Identify the core nodes of death anxiety in breast cancer survivors and analyze its influencing factors; (2) Construct an intervention program for death anxiety in breast cancer survivors based on self-help mindfulness intervention; (3) Evaluate the effectiveness and safety of self-help mindfulness intervention for the intervention of death anxiety in breast cancer survivors. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 癌症远处转移者; 2. 既往有精神性疾病; 3. 存在沟通或阅读理解障碍; 4. 病情严重无法配合者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with distant metastases from cancer; 2. Patients with a history of mental illness; 3. Patients with communication or reading comprehension difficulties; 4. Patients with severe illness who are unable to cooperate. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-05-08 00:00:00至 To 2027-06-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-05-08 00:00:00 至 To 2026-06-10 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采用区组随机化方法(blockrandomization)进行分组。随机序列由独立于研究团队的课题组成员使用在线随机序列生成器(www.randomization.com)生成,区组大小设定为6(1:1分配比例),以确保两组样本量在研究过程中保持平衡。生成的随机分配序列存储在由第三方管理的在线随机化系统中,该系统对所有参与患者招募、数据收集和干预实施的研究人员设置访问权限控制,确保分配隐藏。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study employed block randomization for patient assignment. Random sequences were generated by independent members of the research team using an online random sequence generator (www.randomization.com). The block size was set to 6 (1:1 allocation ratio) to ensure a balanced sample size throughout the study. The generated random assignment sequences were stored in a third-party managed online randomization system. This system implemented access controls for all researchers involved in patient recruitment, data collection, and intervention implementation, ensuring assignment anonymity. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
仅负责结局评估的研究人员对分组情况保持盲态。 |
|
Blinding: |
Researchers responsible only for outcome assessment remained blind to the group assignments. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
我们计划选择不共享原始数据。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
We plan to choose not to share the original data. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
在研究期间,患者的姓名、性别等个人可识别信息将用代号或数字代替,并予以严格的保密,只有相关的研究者知道患者的个人信息,患者的隐私权会得到很好的保护。研究结果可能会在杂志上发表,但不会泄露患者个人的任何可识别信息。如果患者同意参加本项研究,患者所有的医疗资料都将被发起此研究的研发单位的有关人员、相关权威机构查阅或被独立的伦理委员会查阅,以检查研究的操作是否恰当。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
During the study, patients' names, genders, and other personally identifiable information will be replaced with codes or numbers and kept strictly confidential. Only the relevant researchers will know the patients' personal information, ensuring their privacy is well protected. The research results may be published in a journal, but no personally identifiable information of the patients will be disclosed. If a patient agrees to participate in this study, all of their medical records will be reviewed by relevant personnel from the research institution initiating the study, relevant authoritative bodies, or an independent ethics committee to examine the appropriateness of the research procedures. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |